|Bid||7.61 x 800|
|Ask||7.63 x 800|
|Day's Range||6.96 - 7.65|
|52 Week Range||2.36 - 9.81|
|Beta (5Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 09, 2022 - Mar 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.13|
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics second quarter 2022 financial results conference call. With me today is Dr. Todd Brady, our president and chief executive officer. Please note that this morning's conference call contains forward-looking statements regarding future events and the future performance of Aldeyra.
LEXINGTON, Mass., August 05, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended June 30, 2022.